Since 2020, Thailand has used HPV DNA tests as a way to optimise primary screening programmes for cervical cancer. The country conducted internal studies on the cost-effectiveness of HPV tests within primary screening and found it economical. To increase coverage amongst the unscreened or under-screened population, self-sampling was introduced to address cultural and/or religious barriers and increase convenience for those who had routine healthcare services delayed due to Covid-19.

Speaking at the 14th meeting of the Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN 2022), Prof Wichai Termrungruanglert of Chulalongkorn University in Bangkok, Thailand, shares how the Thai healthcare system has responded to the changing needs of the screening population.

Watch the full talk below.